NL-OMON24907已完成不适用
Treatment of Fabry patients > 18 years with enzyme supplementation therapy: comparison of efficacy and toxicity of low dose (0,2 mg/kg) fabrazyme (agalsidase beta) or replagal (agalsidase alfa).
Sponsor: College voor Zorgverzekeringen (dutch health care insurance board).Initiator:Dr. C.E.M. Hollak, internistDept. of Internal Medicine, F4-279Academic Medical CenterPO box 226601100 DD AmsterdamThe Netherlandstel. +31-20-5666071fax: +31-20-6919743e-mail: c.e.hollak@amc.uva.nl0 个研究点目标入组 24 人开始时间: 待定最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 24
研究概览
简要总结
PLoS ONE. 2007 Jul 11;2(7):e598.
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. The patient must have given written informed consent;
- •2. Patients must be 18 years or older;
排除标准
- •1. Patient is pregnant or lactating;
- •2. Patient is unwilling to comply to the evaluation program.
研究者
相似试验
已完成
不适用
Treatment of Fabry patients greater than 18 years with enzyme supplementation therapy: comparison of efficacy and toxicity of low dose (0.2 mg/kg) Fabrazyme® (agalsidase beta) or Replagal® (agalsidase alfa)Fabry diseaseNutritional, Metabolic, EndocrineISRCTN45178534Academic Medical Centre (AMC) (The Netherlands)34
已完成
不适用
The Efficacy and Safety of Switch Between Agalsidase Beta to Agalsidase Alfa for Enzyme Replacement in Patients With Anderson-Fabry DiseaseFabry´s DiseaseAnderson-Fabry DiseaseFabry DiseaseNCT01268241CENTOGENE GmbH Rostock200
终止
不适用
Enzyme Replacement Therapy in Fabry DiseaseFabry DiseaseNCT00149318Mario Negri Institute for Pharmacological Research2
Unknown
不适用
Epidemiological Study of Fabry Disease Screening in Chronic Kidney Disease PatientsFabry DiseaseNCT05056636Chang Gung Memorial Hospital2,000
已完成
不适用
Fabry : National Initiative of ScreeningIschemic Stroke HospitalizedNCT00484549University Hospital, Clermont-Ferrand889